Amicus Therapeutics

Amicus Therapeutics

Discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases
Middlesex County United States (HQ)
Deals in the last 12 months undisclosed

Company information

Edit
Launch date
Employees
531 people
Ownership
Market cap
$5.8b
Net debt
$127m
Firm valuation
€5.2b (Public information from 2020)
Revenues, earnings & profits over time
USD20162017201820192020E2021E2022E
Revenues-36m91m182m259m338m474m
% growth--153 %100 %42 %31 %40 %
EBITDA-(438m)(325m)(299m)(214m)(132m)(54m)
% EBITDA margin-(1217 %)(357 %)(164 %)(83 %)(39 %)(11 %)
Profit-(284m)(349m)(356m)(255m)(186m)(84m)
% profit margin-(789 %)(384 %)(196 %)(98 %)(55 %)(18 %)
EV / Revenue-59.5x17.9x12.0x21.9x17.5x12.2x
EV / EBITDA--5.0x-5.0x-7.3x-26.5x-44.6x-107.0x
  • Edit
DateInvestorsAmountRound
$55mSERIES C
N/AN/AIPO
$31.3mPOST IPO EQUITY
$18.6mPOST IPO EQUITY
$10mPOST IPO DEBT
Total Funding€80m

Recent News about Amicus Therapeutics

Edit
LocationEdit
1 Cedarbrook Dr, East Windsor, NJ 08512, USA
Are you an employee or an investor of this company?
Add your profile